These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 16584394)

  • 21. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of chronic hepatitis C].
    Ferenci P
    Wien Med Wochenschr; 2000; 150(23-24):481-5. PubMed ID: 11205179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
    Milazzo L; Biasin M; Gatti N; Piacentini L; Niero F; Zanone Poma B; Galli M; Moroni M; Clerici M; Riva A
    Am J Gastroenterol; 2006 Feb; 101(2):399-402. PubMed ID: 16454849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
    Russo MW; Goldsweig CD; Jacobson IM; Brown RS
    Am J Gastroenterol; 2003 Jul; 98(7):1610-5. PubMed ID: 12873587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of response to therapy for chronic hepatitis C.
    Ferenci P
    Semin Liver Dis; 2004; 24 Suppl 2():25-31. PubMed ID: 15346243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin.
    Boulestin A; Sandres-Saune K; Alric L; Pipy B; Dubois M; Vinel JP; Izopet J
    Antivir Ther; 2005; 10(4):499-504. PubMed ID: 16038475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
    World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
    Mangia A; Leandro G; Helbling B; Renner EL; Tabone M; Sidoli L; Caronia S; Foster GR; Zeuzem S; Berg T; Di Marco V; Cino N; Andriulli A
    J Hepatol; 2004 Mar; 40(3):478-83. PubMed ID: 15123363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.
    Ho SB; Aqel B; Dieperink E; Liu S; Tetrick L; Falck-Ytter Y; DeComarmond C; Smith CI; McKee DP; Boyd W; Kulig CC; Bini EJ; Pedrosa MC
    Dig Dis Sci; 2011 Mar; 56(3):880-8. PubMed ID: 21221804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
    Di Martino V; Boudjema H; Delacour T; Cazier A; Caron C; Coutarel P; Dumouchel P; Cadranel JF
    Clin Infect Dis; 2001 Mar; 32(5):830-1. PubMed ID: 11229855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.
    Layden TJ; Layden JE; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):334-9. PubMed ID: 12225327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.
    Pockros PJ; Reindollar R; McHutchinson J; Reddy R; Wright T; Boyd DG; Wilkes LB
    J Viral Hepat; 2003 Jan; 10(1):55-60. PubMed ID: 12558913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
    van Leeuwen DJ; Yee LJ; Langner RG
    Am J Gastroenterol; 2002 Feb; 97(2):497-8. PubMed ID: 11866304
    [No Abstract]   [Full Text] [Related]  

  • 37. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
    Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic hepatitis C. A new chance with Consensus Interferon for patients with handicaps].
    MMW Fortschr Med; 2002 Nov; 144(45):56-7. PubMed ID: 12534066
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
    Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
    Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.